Insider trades
SEC Form 4 · reported within 2 business days172,894 transactions stored · last updated 2026-09-10 01:01:26 UTC · export this view: JSON · CSV · RSS
Open-market buysOpen-market sellsBuys $1M+Sells $1M+Discretionary sells10b5-1 plan sellsDirector trades10% owners
MatchesEvery transaction matching the current filters, including grants, gifts, and exercises.30
BuysPurchases that moved money (value > $0) and their total. Grants, gifts, and $0 conversions are excluded from the dollar flow.4 / $82.5K
SellsSales that moved money (value > $0) and their total. Trades with no stated price are excluded from the dollar flow.13 / $3.22M
Net flowBuy value minus sell value across the priced trades above. Positive = net buying, negative = net selling.$-3.14M
▲ $82.5K bought$3.22M sold ▼
Cluster activity: 2 or more insiders trading the same stock on the open market in the last 30 days (146 buy / 663 sell)
| Side | Ticker | Company | Insiders | Trades | Total |
|---|---|---|---|---|---|
| ▲ buy | TSM | TAIWAN SEMICONDUCTOR MANUFACTURING CO LTD | 30 | 34 | $295.9K |
| ▲ buy | NONE | WILSON BANK HOLDING CO | 19 | 25 | $95.64M |
| ▲ buy | AMRZ | Amrize Ltd | 11 | 17 | $2.64M |
| ▲ buy | N/A | John Hancock GA Senior Loan Trust | 8 | 9 | $80.79M |
| ▲ buy | CDNL | Cardinal Infrastructure Group Inc. | 7 | 13 | $8.54M |
| ▲ buy | CODI | Compass Diversified Holdings | 6 | 8 | $2.43M |
| ▲ buy | WIX | Wix.com Ltd. | 6 | 8 | $185.7K |
| ▲ buy | ACON | Aclarion, Inc. | 6 | 6 | $125.7K |
| ▲ buy | LIEN | Chicago Atlantic BDC, Inc. | 5 | 18 | $1.22M |
| ▲ buy | DKL | Delek Logistics Partners, LP | 5 | 5 | $750.0K |
| ▲ buy | GPUS | Hyperscale Data, Inc. | 5 | 14 | $646.2K |
| ▲ buy | BMRA | BIOMERICA INC | 5 | 5 | $158.0K |
| ▲ buy | XRN | Chiron Real Estate Inc. | 4 | 6 | $1.30M |
| ▲ buy | INV | Innventure, Inc. | 4 | 4 | $807.8K |
| ▲ buy | AMRC | Ameresco, Inc. | 4 | 10 | $764.3K |
| ▲ buy | TISI | TEAM INC | 4 | 8 | $621.6K |
| ▲ buy | EMBC | Embecta Corp. | 4 | 4 | $557.9K |
| ▲ buy | FOCL | EDAP TMS SA | 4 | 4 | $408.5K |
| ▲ buy | UAMY | UNITED STATES ANTIMONY CORP | 4 | 4 | $298.7K |
| ▲ buy | QNRX | Quoin Pharmaceuticals, Ltd. | 4 | 8 | $280.0K |
Most active insiders by open-market value in the last 30 days
· net API
Sector flows: net open-market value by industry in the last 30 days
· JSON
| Industry | Tickers | Trades | Bought | Sold | Net flow |
|---|---|---|---|---|---|
| Services-Prepackaged Software | 97 | 1524 | $1.07M | $254.33B | $-254.33B |
| Real Estate Investment Trusts | 50 | 180 | $36.14M | $3.70B | $-3.66B |
| Semiconductors & Related Devices | 49 | 591 | $11.12M | $1.31B | $-1.30B |
| Footwear, (No Rubber) | 2 | 2 | $0 | $1.10B | $-1.10B |
| Refuse Systems | 5 | 81 | $1.04B | $2.84M | $1.03B |
| Finance Services | 43 | 399 | $23.30M | $763.10M | $-739.80M |
| Pharmaceutical Preparations | 140 | 907 | $133.54M | $816.15M | $-682.60M |
| Refrigeration & Service Industry Machinery | 6 | 16 | $1.44M | $597.13M | $-595.68M |
| Services-Home Health Care Services | 2 | 21 | $0 | $560.13M | $-560.13M |
| Services-Computer Integrated Systems Design | 14 | 80 | $4.29M | $541.92M | $-537.63M |
| Retail-Miscellaneous Retail | 6 | 46 | $0 | $484.67M | $-484.67M |
| Services-Computer Processing & Data Preparation | 28 | 197 | $963.3K | $402.46M | $-401.50M |
How to read this
- Filed
- Date the Form 4 was filed with the SEC. Insiders must file within 2 business days of the trade.
- Ticker
- The issuer's stock symbol. Select it to open that company's insider-activity page.
- Issuer
- The company whose shares were traded.
- Sector
- The issuer's industry (SEC SIC classification). Select a value to filter to that sector.
- Insider
- The reporting person: an officer, director, or 10% owner. Select a name to see all of their trades.
- Role
- The insider's relationship to the company: director, officer, or 10% owner.
- Code
- SEC transaction code describing the kind of transaction. Full official definitions are under “Transaction codes” below. A dot marks an open-market trade (P/S), the highest-conviction signal.
- Side
- Direction of the trade, from the filing's Acquired (A) ▲ / Disposed of (D) ▼ field: a buy or a sell.
- 10b5-1
- Trade made under a pre-arranged Rule 10b5-1 plan: scheduled in advance, not a discretionary decision (generally lower signal).
- Shares
- Number of shares in this transaction.
- Price
- Reported price per share. Blank for grants, gifts, and other trades with no stated price.
- Value
- Transaction value = shares × price. Left blank for grants, option exercises, gifts, and conversions, which have no cash price (see Own Δ for their impact).
- Owned after
- Form 4 column “Amount of Securities Beneficially Owned Following Reported Transaction(s)”: shares the insider held (directly or indirectly) immediately after this trade.
- Own Δ
- How much this trade changed the insider's own holding versus what they held just before it (not a share of the company). +45% grew it by 45%, 2.0× more than doubled it, −100% sold the entire stake, “new” built a position from nothing.
- Co. Δ
- Change in the insider's stake as a share of the whole company from this trade (transaction shares ÷ shares outstanding). The “(now …)” figure is their resulting total stake. Based on the latest reported shares outstanding; blank when unavailable.
- D/I
- Form 4 column “Ownership Form: Direct (D) or Indirect (I)”. Indirect holdings (for example, through a trust, fund, or family member) are detailed in the filing's “Nature of Indirect Beneficial Ownership.”
- Lag
- Days from the trade date to the filing date (Form 4 is due within 2 business days).
Transaction codes
Verbatim from the SEC's General Instructions for Forms 3, 4 and 5.
- P
- Open market or private purchase of non-derivative or derivative security
- S
- Open market or private sale of non-derivative or derivative security
- A
- Grant, award or other acquisition pursuant to Rule 16b-3(d)
- D
- Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
- F
- Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
- M
- Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
- G
- Bona fide gift
- C
- Conversion of derivative security
- X
- Exercise of in-the-money or at-the-money derivative security
- J
- Other acquisition or disposition (describe transaction)
| Filed ↓Date the Form 4 was filed with the SEC. Insiders must file within 2 business days of the trade. | Ticker | Issuer | SectorIssuer's industry (SEC SIC classification). Select a value in the table to filter to that sector. | Insider | Role | CodeSEC transaction code describing the kind of transaction. See “How to read this” above for the official SEC definition of each code. The dot marks an open-market trade (P/S), the highest-conviction signal. | SideDirection of the trade, from the filing: a buy (acquired ▲) or a sell (disposed ▼). | Shares | PriceReported price per share. Blank for grants, gifts, and other trades with no stated price. | ValueTransaction value = shares × price. Left blank for grants, option exercises, gifts, and conversions, which have no cash price (see Own Δ for their impact). | Owned afterShares the insider held (directly or indirectly) immediately after this trade. | Own ΔHow much this trade changed the insider's own holding versus what they held just before it (not a share of the company). +45% grew it by 45%, 2.0× more than doubled it, −100% sold the entire stake, “new” built a position from nothing. | Co. ΔChange in the insider's stake as a share of the whole company from this trade (transaction shares ÷ shares outstanding). The “(now …)” figure is their resulting total stake in the company. Based on the latest reported shares outstanding; blank when unavailable. | D/IOwnership form: D = direct, I = indirect (for example, held through a trust, fund, or family member). | LagDays from the trade date to the filing date (Form 4 is due within 2 business days). | Link to SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-08-25 | ARDX | ARDELYX, INC. | Pharmaceutical Preparations | RAAB MICHAEL | Director, Officer (President & CEO) | S | ▼ sell | 19,1780 | $3.86 | $74.0K | 1,619,792 | −1% | −<0.01% (now 0.65%) | D | 5d | filing |
| 2026-08-25 | ARDX | ARDELYX, INC. | Pharmaceutical Preparations | RAAB MICHAEL | Director, Officer (President & CEO) | S | ▼ sell | 8,4110 | $3.86 | $32.4K | 1,638,970 | −0.5% | −<0.01% (now 0.66%) | D | 5d | filing |
| 2026-08-25 | ARDX | ARDELYX, INC. | Pharmaceutical Preparations | RAAB MICHAEL | Director, Officer (President & CEO) | S | ▼ sell | 15,9760 | $3.86 | $61.6K | 1,647,381 | −1.0% | −<0.01% (now 0.66%) | D | 5d | filing |
| 2026-08-25 | ARDX | ARDELYX, INC. | Pharmaceutical Preparations | RAAB MICHAEL | Director, Officer (President & CEO) | S | ▼ sell | 15,0090 | $3.86 | $57.9K | 1,663,357 | −0.9% | −<0.01% (now 0.67%) | D | 5d | filing |
| 2026-07-17 | ARDX | ARDELYX, INC. | Pharmaceutical Preparations | RAAB MICHAEL | Director, Officer (President & CEO) | M | ▼ sell10b5-1 | 20,834→ 20,834 Common Stock | — | — | 290,834 | — | — | D | 2d | filing |
| 2026-07-17 | ARDX | ARDELYX, INC. | Pharmaceutical Preparations | RAAB MICHAEL | Director, Officer (President & CEO) | S | ▼ sell10b5-1 | 41,6680 | $5.06 | $210.9K | 1,678,366 | −2% | −0.02% (now 0.67%) | D | 2d | filing |
| 2026-07-17 | ARDX | ARDELYX, INC. | Pharmaceutical Preparations | RAAB MICHAEL | Director, Officer (President & CEO) | M | ▲ buy10b5-1 | 20,8340 | $0.99 | $20.6K | 1,720,034 | +1% | +<0.01% (now 0.69%) | D | 2d | filing |
| 2026-06-17 | ARDX | ARDELYX, INC. | Pharmaceutical Preparations | RAAB MICHAEL | Director, Officer (President & CEO) | M | ▼ sell10b5-1 | 20,833→ 20,833 Common Stock | — | — | 311,668 | — | — | D | 2d | filing |
| 2026-06-17 | ARDX | ARDELYX, INC. | Pharmaceutical Preparations | RAAB MICHAEL | Director, Officer (President & CEO) | S | ▼ sell10b5-1 | 41,6660 | $5.67 | $236.3K | 1,699,200 | −2% | −0.02% (now 0.68%) | D | 2d | filing |
| 2026-06-17 | ARDX | ARDELYX, INC. | Pharmaceutical Preparations | RAAB MICHAEL | Director, Officer (President & CEO) | M | ▲ buy10b5-1 | 20,8330 | $0.99 | $20.6K | 1,740,866 | +1% | +<0.01% (now 0.70%) | D | 2d | filing |
| 2026-05-22 | ARDX | ARDELYX, INC. | Pharmaceutical Preparations | RAAB MICHAEL | Director, Officer (President & CEO) | S | ▼ sell | 14,0280 | $6.27 | $87.9K | 1,720,033 | −0.8% | −<0.01% (now 0.69%) | D | 1d | filing |
| 2026-05-22 | ARDX | ARDELYX, INC. | Pharmaceutical Preparations | RAAB MICHAEL | Director, Officer (President & CEO) | S | ▼ sell | 17,9260 | $6.27 | $112.4K | 1,734,061 | −1% | −<0.01% (now 0.70%) | D | 1d | filing |
| 2026-05-22 | ARDX | ARDELYX, INC. | Pharmaceutical Preparations | RAAB MICHAEL | Director, Officer (President & CEO) | S | ▼ sell | 7,8610 | $6.27 | $49.3K | 1,751,987 | −0.4% | −<0.01% (now 0.70%) | D | 1d | filing |
| 2026-05-22 | ARDX | ARDELYX, INC. | Pharmaceutical Preparations | RAAB MICHAEL | Director, Officer (President & CEO) | S | ▼ sell | 14,9330 | $6.27 | $93.6K | 1,759,848 | −0.8% | −<0.01% (now 0.71%) | D | 1d | filing |
| 2026-05-19 | ARDX | ARDELYX, INC. | Pharmaceutical Preparations | RAAB MICHAEL | Director, Officer (President & CEO) | M | ▼ sell10b5-1 | 20,833→ 20,833 Common Stock | — | — | 332,501 | — | — | D | 4d | filing |
| 2026-05-19 | ARDX | ARDELYX, INC. | Pharmaceutical Preparations | RAAB MICHAEL | Director, Officer (President & CEO) | S | ▼ sell10b5-1 | 41,6660 | $6.28 | $261.6K | 1,774,781 | −2% | −0.02% (now 0.71%) | D | 4d | filing |
| 2026-05-19 | ARDX | ARDELYX, INC. | Pharmaceutical Preparations | RAAB MICHAEL | Director, Officer (President & CEO) | M | ▲ buy10b5-1 | 20,8330 | $0.99 | $20.6K | 1,816,447 | +1% | +<0.01% (now 0.73%) | D | 4d | filing |
| 2026-04-27 | FOLD | AMICUS THERAPEUTICS, INC. | Pharmaceutical Preparations | RAAB MICHAEL | Director | D | ▼ sell | 74,872→ 74,872 Common Stock | — | — | 0 | — | — | D | 0d | filing |
| 2026-04-27 | FOLD | AMICUS THERAPEUTICS, INC. | Pharmaceutical Preparations | RAAB MICHAEL | Director | D | ▼ sell | 42,467→ 42,467 Common Stock | — | — | 0 | — | — | D | 0d | filing |
| 2026-04-27 | FOLD | AMICUS THERAPEUTICS, INC. | Pharmaceutical Preparations | RAAB MICHAEL | Director | D | ▼ sell | 30,474→ 30,474 Common Stock | — | — | 0 | — | — | D | 0d | filing |
| 2026-04-27 | FOLD | AMICUS THERAPEUTICS, INC. | Pharmaceutical Preparations | RAAB MICHAEL | Director | D | ▼ sell | 45,423→ 45,423 Common Stock | — | — | 0 | — | — | D | 0d | filing |
| 2026-04-27 | FOLD | AMICUS THERAPEUTICS, INC. | Pharmaceutical Preparations | RAAB MICHAEL | Director | D | ▼ sell | 36,111→ 36,111 Common Stock | — | — | 0 | — | — | D | 0d | filing |
| 2026-04-27 | FOLD | AMICUS THERAPEUTICS, INC. | Pharmaceutical Preparations | RAAB MICHAEL | Director | D | ▼ sell | 18,574→ 18,574 Common Stock | — | — | 0 | — | — | D | 0d | filing |
| 2026-04-27 | FOLD | AMICUS THERAPEUTICS, INC. | Pharmaceutical Preparations | RAAB MICHAEL | Director | D | ▼ sell | 19,473→ 19,473 Common Stock | — | — | 0 | — | — | D | 0d | filing |
| 2026-04-27 | FOLD | AMICUS THERAPEUTICS, INC. | Pharmaceutical Preparations | RAAB MICHAEL | Director | D | ▼ sell | 16,236→ 16,236 Common Stock | — | — | 0 | — | — | D | 0d | filing |
| 2026-04-27 | FOLD | AMICUS THERAPEUTICS, INC. | Pharmaceutical Preparations | RAAB MICHAEL | Director | D | ▼ sell | 20,000→ 20,000 Common Stock | — | — | 0 | — | — | D | 0d | filing |
| 2026-04-27 | FOLD | AMICUS THERAPEUTICS, INC. | Pharmaceutical Preparations | RAAB MICHAEL | Director | D | ▼ sell | 115,8570 | $14.50 | $1.68M | 0 | −100% | −0.04% (now 0%) | D | 0d | filing |
| 2026-04-17 | ARDX | ARDELYX, INC. | Pharmaceutical Preparations | RAAB MICHAEL | Director, Officer (President & CEO) | M | ▼ sell10b5-1 | 20,834→ 20,834 Common Stock | — | — | 353,334 | — | — | D | 2d | filing |
| 2026-04-17 | ARDX | ARDELYX, INC. | Pharmaceutical Preparations | RAAB MICHAEL | Director, Officer (President & CEO) | S | ▼ sell10b5-1 | 41,6680 | $6.29 | $262.0K | 1,795,614 | −2% | −0.02% (now 0.72%) | D | 2d | filing |
| 2026-04-17 | ARDX | ARDELYX, INC. | Pharmaceutical Preparations | RAAB MICHAEL | Director, Officer (President & CEO) | M | ▲ buy10b5-1 | 20,8340 | $0.99 | $20.6K | 1,837,282 | +1% | +<0.01% (now 0.74%) | D | 2d | filing |
Open “How to read this” above for definitions of every column and code. Select a column heading to sort.